In small cell lung cancer, subcutaneous tarlatamab (from the DeLLphi-308 Phase 1b study) showed safety and early activity, expanding options for patients after platinum-based chemotherapy. Separately, the randomized Phase 2 DeLLphi-309 results reported that longer gaps between tarlatamab doses may work in the disease setting, presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer in Seoul. Together, the reports emphasize both administration logistics and dosing schedules—two practical barriers that often shape real-world adoption of novel immunotherapies. For biotech and oncology leaders, the combined updates provide additional evidence for ongoing clinical development choices and potential protocol flexibility as more patients and follow-up data accrue.